Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on October 21, 2004, to report its third-quarter financial results ended September 30, 2004, as announced in a press release issued that same day. The filing primarily serves to furnish the earnings press release as an exhibit and to provide context for the financial information presented. Gilead management utilizes non-GAAP financial measures to assess ongoing results, excluding specific items deemed unusual due to their nature, size, or infrequency.
Key Highlights
- 1Gilead Sciences announced its third-quarter 2004 financial results on October 21, 2004.
- 2The 8-K filing primarily incorporates an earnings press release (Exhibit 99.1) detailing these results.
- 3The company uses non-GAAP financial measures to provide insights into core business performance, excluding unusual items.
- 4Specific unusual items mentioned include a fair value gain on EyeTech Pharmaceuticals warrants, an in-process R&D charge from the Triangle Pharmaceuticals acquisition, and a vendor settlement payment.
- 5Management believes these non-GAAP measures offer a clearer view of trends affecting the core business for both management and investors.
- 6John F. Milligan, Executive Vice President and Chief Financial Officer, signed the report.